"Postexposure protection of guinea pigs against a lethal Ebola virus challenge by RNAi" J.Infectious Disease 193(12)1650 June/06 Authors showed SNALP delivery of 4 siRNAs provided protection, and then showed that even one of the four siRNAs would completely protect the guinea pigs.
Why? Who would go through the cost of developing a drug to protect from Ebola, when malaria infects >300 million a year killing more than a 1 million. Ebola kills maybe 30 people every couple of years.
I'm not sure the government has to license technology that is patented in the US based on work paid for by grants from the US government. But I'll go with it. If we can outsource security in Iraq, surely outsourcing bioweapons research is no big deal.
The government would indeed have to pay to license the technology if they were to use it. IP is the reason to own this stock. and they (probably with RNAI) have the IP sewn up for 20 plus years. Why do you think every major pharma is already partnered of talking to RNAI and ALNY? IP.
Military ventures and commercial ventures are very different. For certain funding mechanisms like those from NIH and the DOD, if patents come out of them, the government is not required to pay licensing fees to use the technology. No academic lab needs to license RNAi technology, which is essentially the same thing.